Propranolol and infantile hemangiomas four years later: A systematic review

Pediatric Dermatology

Volumn 30, Issue 2, 2013, Pages 182-191

  Marqueling, Ann L ^a,d   Oza, Vikash ^a   Frieden, Ilona J ^a,b   Puttgen, Katherine B ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMIQUIMOD; INTERFERON; PLACEBO; PREDNISONE; PROPRANOLOL; VINCRISTINE;

ACROCYANOSIS; ADRENAL INSUFFICIENCY; APNEA; ARTICLE; BEHAVIOR CHANGE; BRADYCARDIA; BRONCHIOLITIS; BRONCHOSPASM; BRONCHUS HYPERREACTIVITY; CAPILLARY HEMANGIOMA; CASE STUDY; CONSTIPATION; COUGHING; CRYOTHERAPY; CYANOSIS; DENTAL CARIES; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; FATIGUE; FEEDING DISORDER; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL SYMPTOM; GROUPS BY AGE; HUMAN; HYPERGLYCEMIA; HYPERHIDROSIS; HYPOGLYCEMIA; HYPOTENSION; INFANT; INFECTION; INSOMNIA; IRRITABILITY; LETHARGY; LOW LEVEL LASER THERAPY; MUSCLE HYPOTONIA; NIGHTMARE; OBSTRUCTIVE AIRWAY DISEASE; PALLOR; PATHOLOGIC FOOD REFUSAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; RESTLESSNESS; RETROSPECTIVE STUDY; SCLEROTHERAPY; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; STREPTOCOCCUS INFECTION; STRIDOR; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR LOCALIZATION; ULCER; UPPER RESPIRATORY TRACT INFECTION; VIRAL GASTROENTERITIS; VOMITING; WHEEZING;

ADRENERGIC BETA-ANTAGONISTS; FEMALE; HEMANGIOMA; HUMANS; INFANT; MALE; PROPRANOLOL; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84874944656     PISSN: 07368046     EISSN: 15251470     Source Type: Journal    
DOI: 10.1111/pde.12089     Document Type: Article

References (57)

1. Hoornweg MJ, Smeulders MJC, Ubbink DT, et al. The prevalence and risk factors of infantile haemangiomas: a case-control study in the Dutch population. Paediatr Perinat Epidemiol 2012; 26: 156-162.
2. Kilcline C, Frieden IJ,. Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr Dermatol 2008; 25: 168-173.
3. Kanada KN, Merin MR, Munden A, et al. A prospective study of cutaneous findings in newborns in the United States: correlation with race, ethnicity, and gestational status using updated classification and nomenclature. J Pediatr 2012; 161: 240-245.
4. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358: 2649-2651.
5. Hogeling M, Adams S, Wargon O,. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics 2011; 128: e259-e266.
6. Cheng JF, Gole GA, Sullivan TJ,. Propranolol in the management of periorbital infantile haemangioma. Clin Exp Ophthalmol 2010; 38: 547-553.
7. Haider KM, Plager DA, Neely DE, et al. Outpatient treatment of periocular infantile hemangiomas with oral propranolol. J AAPOS 2010; 14: 251-256.
8. Claerhout I, Buijsrogge M, Delbeke P, et al. The use of propranolol in the treatment of periocular infantile haemangiomas: a review. Br J Ophthalmol 2011; 95: 1199-1202.
9. Dhaybi Al R, Superstein R, Milet A, et al. Treatment of periocular infantile hemangiomas with propranolol: case series of 18 children. Ophthalmology 2011; 118: 1184-1188.
10. Missoi TG, Lueder GT, Gilbertson K, et al. Oral propranolol for treatment of periocular infantile hemangiomas. Arch Ophthalmol 2011; 129: 899-903.
11. Snir M, Reich U, Siegel R, et al. Refractive and structural changes in infantile periocular capillary haemangioma treated with propranolol. Eye (London) 2011; 25: 1627-1634.
12. El-Essawy R, Galal R, Abdelbaki S,. Nonselective β-blocker propranolol for orbital and periorbital hemangiomas in infants: a new first-line of treatment? Clin Ophthalmol 2011; 5: 1639-1644.
13. Leboulanger N, Fayoux P, Teissier N, et al. Propranolol in the therapeutic strategy of infantile laryngotracheal hemangioma: a preliminary retrospective study of French experience. Int J Pediatr Otorhinolaryngol 2010; 74: 1254-1257.
14. Weiss I, O TM, Lipari BA, et al. Current treatment of parotid hemangiomas. Laryngoscope 2011; 121: 1642-1650.
15. Chik KK, Luk CK, Chan HB, et al. Use of propranolol in infantile haemangioma among Chinese children. Hong Kong Med J 2010; 16: 341-346.
16. Bertrand J, McCuaig C, Dubois J, et al. Propranolol versus prednisone in the treatment of infantile hemangiomas: a retrospective comparative study. Pediatr Dermatol 2011; 28: 649-654.
17. Fuchsmann C, Quintal M-C, Giguere C, et al. Propranolol as first-line treatment of head and neck hemangiomas. Arch Otolaryngol Head Neck Surg 2011; 137: 471-478.
18. Lv M-M, Fan X-D, Su L-X,. Propranolol for problematic head and neck hemangiomas: an analysis of 37 consecutive patients. Int J Pediatr Otorhinolaryngol 2012; 76: 574-578.
19. Zaher H, Rasheed H, Hegazy RA, et al. Oral propranolol: an effective, safe treatment for infantile hemangiomas. Eur J Dermatol 2011; 21: 558-563.
20. Price CJ, Lattouf C, Baum B, et al. Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis. Arch Dermatol 2011; 147: 1371-1376.
21. Talaat AA, Elbasiouny MS, Elgendy DS, et al. Propranolol treatment of infantile hemangioma: clinical and radiologic evaluations. J Pediatr Surg 2012; 47: 707-714.
22. Bertrand J, Sammour R, McCuaig C, et al. Propranolol in the treatment of problematic infantile hemangioma: review of 35 consecutive patients from a vascular anomalies clinic. J Cutan Med Surg 2012; 16: 115-121.
23. Robinson JK, Dellavalle RP, Bigby M, et al. Systematic reviews: grading recommendations and evidence quality. Arch Dermatol 2008; 144: 97-99.
24. Chang LC, Haggstrom AN, Drolet BA, et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics 2008; 122: 360-367.
25. Zvulunov A, McCuaig C, Frieden IJ, et al. Oral propranolol therapy for infantile hemangiomas beyond the proliferation phase: a multicenter retrospective study. Pediatr Dermatol 2011; 28: 94-98.
26. Sommers Smith SK, Smith DM,. Beta blockade induces apoptosis in cultured capillary endothelial cells. In Vitro Cell Dev Biol Anim 2002; 38: 298-304.
27. Stoschitzky K, Sakotnik A, Lercher P, et al. Influence of beta-blockers on melatonin release. Eur J Clin Pharmacol 1999; 55: 111-115.
28. Abernethy DR, Arendt RM, Greenblatt DJ,. Pharmacologic properties of acebutolol: relationship of hydrophilicity to central nervous system penetration. Am Heart J 1985; 2: 1120-1125.
29. Bennett ML, Fleischer AB, Chamlin SL, et al. Oral corticosteroid use is effective for cutaneous hemangiomas: an evidence-based evaluation. Arch Dermatol 2001; 137: 1208-1213.
30. Tollefson MM, Frieden IJ,. Early growth of infantile hemangiomas: what parents' photographs tell us. Pediatrics 2012; 130: e314-e320.
31. Chakkittakandiyil A, Phillips R, Frieden IJ, et al. Timolol maleate 0.5% or 0.1% gel-forming solution for infantile hemangiomas: a retrospective, multicenter, cohort study. Pediatr Dermatol 2012; 29: 28-31.
32. McMahon P, Oza V, Frieden IJ,. Topical timolol for infantile hemangiomas: putting a note of caution in "cautiously optimistic". Pediatr Dermatol 2012; 29: 127-130.
33. Chambers CB, Katowitz WR, Katowitz JA, et al. A controlled study of topical 0.25% timolol maleate gel for the treatment of cutaneous infantile capillary hemangiomas. Ophthal Plast Reconstr Surg 2012; 28: 103-106.
34. Moehrle M, Léauté-Labrèze C, Schmidt V, et al. Topical timolol for small hemangiomas of infancy. Pediatr Dermatol 2012. Apr 4. doi: 10.1111/j.1525-1470.2012.01723.x [Epub ahead of print].
35. Semkova K, Kazandjieva J,. Topical timolol maleate for treatment of infantile haemangiomas: preliminary results of a prospective study. Clin Exp Dermatol 2012. Jun 25. doi: 10.1111/j.1365-2230.2012.04425.x [Epub ahead of print].
36. Bagazgoitia L, Torrelo A, Gutiérrez JCL, et al. Propranolol for infantile hemangiomas. Pediatr Dermatol 2011; 28: 108-114.
37. Balma-Mena A, Chakkittakandiyil A, Weinstein M, et al. Propranolol in the management of infantile hemangiomas: clinical response and predictors. J Cutan Med Surg 2012; 16: 169-173.
38. Bernabeu-Wittel J, Pereyra-Rodríguez JJ, Mantrana-Bermejo ME, et al. [Propranolol for the treatment of severe hemangiomas of infancy: results from a series of 28 patients]. Actas Dermosifiliogr 2011; 102: 510-516.
39. Blatt J, Morrell DS, Buck S, et al. &-blockers for infantile hemangiomas: a single-institution experience. Clin Pediatr (Phil) 2011; 50: 757-763.
40. Buckmiller LM, Munson PD, Dyamenahalli U, et al. Propranolol for infantile hemangiomas: early experience at a tertiary vascular anomalies center. Laryngoscope 2010; 120: 676-681.
41. Chai Q, Chen W-L, Huang Z-Q, et al. Preliminary experiences in treating infantile hemangioma with propranolol. Ann Plast Surg 2011. May 27. [Epub ahead of print].
42. Corapcioǧlu F, Büyükkapu-Bay S, Binnetoǧlu K, et al. Preliminary results of propranolol treatment for patients with infantile hemangioma. Turk J Pediatr 2011; 53: 137-141.
43. de Graaf M, Breur JMPJ, Raphaël MF, et al. Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants. J Am Acad Dermatol 2011; 65: 320-327.
44. Erbay A, Sarialioglu F, Malbora B, et al. Propranolol for infantile hemangiomas: a preliminary report on efficacy and safety in very low birth weight infants. Turk J Pediatr 2010; 52: 450-456.
45. Gajbhiye V, Nath S, Chatterjee S, et al. Role of propranolol in hemangiomas. J Indian Assoc Pediatr Surg 2011; 16: 173-174.
46. Hermans DJJ, van Beynum IM, Schultze Kool LJ, et al. Propranolol, a very promising treatment for ulceration in infantile hemangiomas: a study of 20 cases with matched historical controls. J Am Acad Dermatol 2011; 64: 833-838.
47. Hermans DJJ, Ottenhof MJ, Wijnen MHWA, et al. [Treatment of haemangiomas of infancy with propranolol; good results, few side effects]. Ned Tijdschr Geneeskd 2011; 155: A3482.
48. Holmes WJM, Mishra A, Gorst C, et al. Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas. J Plast Reconstr Aesthet Surg 2011; 64: 445-451.
49. Hsu T-C, Wang J-D, Chen C-H, et al. Treatment with propranolol for infantile hemangioma in 13 Taiwanese newborns and young infants. Pediatr Neonatol 2012; 53: 125-132.
50. Manunza F, Syed S, Laguda B, et al. Propranolol for complicated infantile haemangiomas: a case series of 30 infants. Br J Dermatol 2010; 162: 466-468.
51. Rössler J, Schill T, Bähr A, et al. Propranolol for proliferating infantile haemangioma is superior to corticosteroid therapy-a retrospective, single centre study. J Eur Acad Dermatol Venereol 2011; 26: 1173-1175.
52. Saint-Jean M, Léauté-Labrèze C, Mazereeuw-Hautier J, et al. Propranolol for treatment of ulcerated infantile hemangiomas. J Am Acad Dermatol 2011; 64: 827-832.
53. Sans V, la Roquede ED, Berge J, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics 2009; 124: e423-e431.
54. Schiestl C, Neuhaus K, Zoller S, et al. Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas. Eur J Pediatr 2011; 170: 493-501.
55. Schupp CJ, Kleber J-B, Günther P, et al. Propranolol therapy in 55 infants with infantile hemangioma: dosage, duration, adverse effects, and outcome. Pediatr Dermatol 2011; 28: 640-644.
56. Tan ST, Itinteang T, Leadbitter P,. Low-dose propranolol for infantile haemangioma. J Plast Reconstr Aesthet Surg 2011; 64: 292-299.
57. Thayal PK, Bhandari PS, Sarin YK,. Comparison of efficacy of intralesional bleomycin and oral propanolol in management of hemangiomas. Plast Reconstr Surg 2012; 129: 733e-735e.